Product InformationRegistration Status: Active
DBL MAGNESIUM SULFATE CONCENTRATED INJECTION 49.3% is approved to be sold in Singapore with effective from 1991-05-21. It is marketed by HOSPIRA SINGAPORE PTE LTD, with the registration number of SIN05860P.
This product contains Magnesium 2.47g/5ml in the form of INJECTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.
This product is manufactured by Hospira Australia Pty Ltd in GERMANY, andhameln pharmaceuticals GmbH in AUSTRALIA.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.
Mechanism of Action
Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca2+ influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.
LD50 = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.
Magnesium sulfate (1:1) | Magnesium sulfate anhydrous | Magnesium sulphate | magnesium(II) sulfate | Magnesiumsulfat | MgSO4 | Magnesium sulfate |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.